

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

**CHANGE OF JOINT COMPANY SECRETARY
AND
RESIGNATION OF NON-EXECUTIVE DIRECTOR**

CHANGE OF JOINT COMPANY SECRETARY

The Board announces that with effect from 26 November 2021:

- (1) Dr. Jie CHEN has resigned as a Joint Company Secretary under the Listing Rules due to changing in work scope within the Group; and
- (2) Ms. Yan LU has been appointed as a Joint Company Secretary.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Wei ZHANG has resigned as a non-executive Director with effect from 26 November 2021 due to pursuit of his personal commitments.

CHANGE OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Dr. Jie CHEN (“**Dr. CHEN**”) has resigned as a joint company secretary of the Company (a “**Joint Company Secretary**”) with effect from 26 November 2021 due to changing in work scope within the Group. Dr. CHEN will remain to be a deputy general manager of the Group.

Dr. CHEN has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation as a Joint Company Secretary that needs to be brought to the attention of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its gratitude to Dr. CHEN for her valuable contribution to the Company during her tenure of service as a Joint Company Secretary.

The Board further announces that Ms. Yan LU (“**Ms. LU**”) has been appointed by the Board as a Joint Company Secretary with effect from 26 November 2021.

The biography of Ms. LU is set out below:

Ms. LU, aged 39, was appointed as the Chief Financial Officer of the Group in December 2019. Ms. LU is primarily responsible for financial internal control, investor relations, public relations and treasury management of the Group. Prior to joining the Group, Ms. LU has over 13 years of experience in investment banking business. Ms. LU joined GF Capital (Hong Kong) Limited in July 2018 with her last position as the director, head of investment banking business and managing director. From September 2007 to July 2018, Ms. LU worked at UBS Securities Hong Kong Limited with her last position as an executive director in the Asian healthcare group. She has been a signing Principal for Hong Kong initial public offerings (IPO) since 2014. Ms. LU obtained her master’s degree in finance from Guanghua School of Management in Peking University (北京大學), and her bachelor’s degree in finance in Renmin University of China (中國人民大學).

Waiver from strict compliance with rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”)

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Dr. CHEN to act as a Joint Company Secretary for a period from 26 March 2021 to 21 May 2023 (the “**Waiver Period**”), on the condition that Dr. CHEN would be assisted by Ms. Wing Han Sharon LEUNG (“**Ms. LEUNG**”), the other Joint Company Secretary, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in announcement of the Company dated 26 March 2021.

Given that the condition to the Waiver could no longer be fulfilled following the resignation of Dr. CHEN and appointment of Ms. LU, the Company has applied to the Stock Exchange and has already been granted with a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from 26 November 2021 to 25 November 2024 (the “**New Waiver Period**”) in relation to the eligibility of Ms. LU to act as a Joint Company Secretary, on the conditions that:

- i. Ms. LU will be assisted by Ms. LEUNG during the New Waiver Period; and
- ii. the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the New Waiver Period, the Company must demonstrate to the Stock Exchange’s satisfaction that Ms. LU, having had the benefit of Ms. LEUNG’s assistance, has acquired the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary.

The Company is of the view that while it is important for company secretary to possess the acceptable qualification or relevant experience under Rule 3.28 of the Listing Rules, it is also vital for the company secretary to have experience relevant to the Group's industry and operations, and close working relationship with the management, the Board and Shareholders in order to perform the function of a company secretary and to take the necessary actions in the most effective manner. While Ms. LU currently does not possess the acceptable qualification or sufficient experience under Rules 3.28 of the Listing Rules, Ms. LU, being the existing Chief Financial Officer of the Group, has substantial familiarity with the day-to-day operations of the Group and has had close working relationship with the Board and other core management members since she joined the Group. Furthermore, as Ms. LU is primarily responsible for the investor relations and public relations management of the Group, she was heavily involved in information disclosure. She has been actively involved in communications with the Board and Shareholders, organising Board and Shareholders' meetings and is the key contact person of the Board and Shareholders. In light of the foregoing, Ms. LU has accumulated extensive experience in handling company secretarial matters. As such, the Board considers it the most efficient to maintain joint company secretary arrangement so that Ms. LU will be assisted by Ms. LEUNG to attain the relevant experience during the New Waiver Period and become capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Wei ZHANG (“**Mr. ZHANG**”) has resigned as a non-executive Director with effect from 26 November 2021 due to pursuit of his personal commitments.

Mr. ZHANG has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. ZHANG for his valuable contributions to the Company during his tenure of service.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, 26 November 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*